ClassID:

96695

C07K5/06113 - CPC Classification

Classification description:

Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links; Dipeptides with the first amino acid being acidic Asp- or Asn-amino acid

Sub-classes:
Recent Application in this class:
#1
20250282826
2025-09-11

PREPARATION METHOD, INTERMEDIATES, AND USE OF CYCLIC PEPTIDE TOXIN ALPHA-AMANITIN AND/OR AMANINAMIDE

#2
20250170253
2025-05-29

CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS

#3
20240425547
2024-12-26

PSMA Imaging Agents

#4
20240409580
2024-12-12

PSMA Imaging Agents

#5
20240285584
2024-08-29

AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDERECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS

#6
20240254165
2024-08-01

METHOD FOR PRODUCING GLYCOPEPTIDE

#7
20240201189
2024-06-20

FLUORESCENT PROBE FOR USE IN DETECTION OF PANCREATIC CANCER

#8
20230390408
2023-12-07

LINKER COMPOUNDS COMPRISING AMIDE BONDS

#9
20220315507
2022-10-06

PSMA BINDER AND USE THEREOF

#10
20220265841
2022-08-25

CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS

#11
20220202777
2022-06-30

AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS

#12
20210188905
2021-06-24

COMBINING BETA-DIPEPTIDES AND AMINO ACIDS FOR OPTIMAL NUTRITIONAL SUPPLEMENTATION

#13
20210163880
2021-06-03

BIOLOGICALLY ACTIVE C-TERMINAL ARGININE-CONTAINING PEPTIDES

#14
20210154312
2021-05-27

CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS

#15
20210154311
2021-05-27

CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS

#16
20210032286
2021-02-04

PSMA Imaging Agents

#17
20210024574
2021-01-28

PSMA imaging agents

#18
20200377549
2020-12-03

PSMA imaging agents

#19
20200299226
2020-09-24

Mild and efficient preparation method for α-acyloxyenamide compounds and use thereof in synthesis of amide and polypeptide

#20
20200237637
2020-07-30

N-acyldipeptide derivatives and their uses

#21
20200207809
2020-07-02

Tripeptide epoxy ketone protease inhibitors

#22
20190343804
2019-11-14

Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

#23
20190314515
2019-10-17

CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS

#24
20190210957
2019-07-11

Mild and efficient preparation method for α-acyloxyenamide compounds and use thereof in synthesis of amide and polypeptide

#25
20190083631
2019-03-21

Carbonic anhydrase IX inhibitor conjugates and uses thereof

#26
20180360669
2018-12-20

Skin treatment devices and methods with pre-stressed configurations

#27
20180303741
2018-10-25

Combination of N-acyldipeptide derivatives and retinol, and methods of use thereof

#28
20180289826
2018-10-11

CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS

#29
20180271991
2018-09-27

CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS

#30
20180258134
2018-09-13

PSMA imaging agents

#31
20180256737
2018-09-13

Conjugates for treating diseases caused by PSMA expressing cells

#32
20180256736
2018-09-13

CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS

#33
20180256735
2018-09-13

CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS

#34
20180256734
2018-09-13

CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS

#35
20180256733
2018-09-13

CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS

#36
20180228772
2018-08-16

Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

#37
20180186833
2018-07-05

Selective cysteine protease inhibitors and uses thereof

#38
20180043036
2018-02-15

Lipid assemblies and uses thereof and some pH and electrostatic modulating lipids to be used in said assemblies

#39
20170321187
2017-11-09

BIOLOGICALLY ACTIVE C-TERMINAL ARGININE-CONTAINING PEPTIDES

#40
20170260231
2017-09-14

Substrates and inhibitors of prolyl oligopeptidase and methods of use thereof

#41
20170121366
2017-05-04

Dipeptides as inhibitors of human immunoproteasomes

#42
20170119737
2017-05-04

Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

#43
20170119646
2017-05-04

N-acyldipeptide derivatives and their uses

#44
20170088813
2017-03-30

Biologically active C-terminal arginine-containing peptides

#45
20160368946
2016-12-22

Tripeptide epoxy ketone protease inhibitors

#46
20160361376
2016-12-15

Conjugates for treating diseases caused by PSMA expressing cells

#47
20160347730
2016-12-01

Methods of producing cancer targeting compounds

#48
20160347706
2016-12-01

Methods of producing cancer treating compounds

#49
20160304555
2016-10-20

PSMA imaging agents

#50
20160235711
2016-08-18

Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

#51
20160213522
2016-07-28

Skin treatment devices and methods with pre-stressed configurations

#52
20160074304
2016-03-17

Gellant

#53
20160030589
2016-02-04

Methods of producing cancer compounds

#54
20150368294
2015-12-24

Gadd45beta targeting agents

#55
20150367028
2015-12-24

Amphiphilic linear peptide/peptoid and hydrogel comprising the same

#56
20150353601
2015-12-10

Compounds for enzyme inhibition

#57
20150337024
2015-11-26

Lead compound for otoprotection: targeting HGF signaling with dihexa

#58
20150297735
2015-10-22

Conjugates for treating diseases caused by PSMA expressing cells

#59
20150212078
2015-07-30

Pro-substrates for live cell applications

#60
20150197782
2015-07-16

DNA encoding dipeptide-synthesizing enzyme (variants), bacterium belonging to the genus , and methods for producing dipeptides using thereof

#61
20150183822
2015-07-02

ANGIOTENSIN-CONVERTING-ENZYME INHIBITING DIPEPTIDE

#62
20150175662
2015-06-25

Peptides and use thereof

#63
20150148395
2015-05-28

Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

#64
20150119330
2015-04-30

Substrates and inhibitors of prolyl oligopeptidase and methods of use

#65
20150111828
2015-04-23

Dipeptide mimetics of NGF and BDNF neurotrophins

#66
20150065564
2015-03-05

Lipoyl compounds and methods for treating ischemic injury

#67
20150038416
2015-02-05

GLP-1 receptor modulators

#68
20140094614
2014-04-03

Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

#69
20140038903
2014-02-06

Selective cysteine protease inhibitors and uses thereof

#70
20130237483
2013-09-12

Lipoyl compounds and their use for treating ischemic injury

#71
20130184629
2013-07-18

Skin treatment devices and methods with pre-stressed configurations

#72
20130053303
2013-02-28

Compounds for enzyme inhibition

#73
20130041008
2013-02-14

Compounds for enzyme inhibition

#74
20130035297
2013-02-07

Compounds for enzyme inhibition

#75
20130023475
2013-01-24

C-Met receptor regulation by angiotensin IV (AT4) receptor ligands

#76
20130023460
2013-01-24

Amphiphilic linear peptide/peptoid and hydrogel comprising the same

#77
20120301918
2012-11-29

Method for producing α-L-aspartyl-L-phenylalanine-β-ester and method for producing α-L-aspartyl-L-phenylalanine-α-methyl ester

#78
20120295304
2012-11-22

Method for producing α-L-aspartyl-L-phenylalanine-β-ester and method for producing α-L-aspartyl-L-phenylalanine-α-methyl ester

#79
20120277164
2012-11-01

Gadd45beta targeting agents

#80
20120270813
2012-10-25

Process for preparing peptide products for promoting cholecystokinin secretion and use of the peptide products

#81
20120252743
2012-10-04

Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors IIa and Xa

#82
20120088762
2012-04-12

Compounds for enzyme inhibition

#83
20120046591
2012-02-23

Treatment devices and methods with extending elements

#84
20120046586
2012-02-23

Skin treatment devices and methods with pre-stressed configurations

#85
20120003692
2012-01-05

Method for producing α-L-aspartyl-L-phenylalanine-β-ester and method for producing α-L-aspartyl-L-phenylalanine-α-methyl ester

#86
20110312895
2011-12-22

DIPEPTIDE MIMETICS OF NGF AND BDNF NEUROTROPHINS

#87
20110294719
2011-12-01

Dipeptoid prodrugs and the use thereof

#88
20110250153
2011-10-13

Oligomeric biosurfactants in dermatocosmetic compositions

#89
20110206709
2011-08-25

T-cell antigen peptide from allergen for stimulation of IL-10 production

#90
20110184147
2011-07-28

ENZYME SUBSTRATE FOR LABELING OF PROTEIN

#91
20110183925
2011-07-28

ANTI-INFLAMMATORY PEPTIDE

#92
20110183413
2011-07-28

Biologically active C-terminal arginine-containing peptides

#93
20110171690
2011-07-14

Angiotensin converting enzyme inhibitory peptide

#94
20100279343
2010-11-04

Method for producing α-L-aspartyl-L-phenylalanine-β-ester and method for producing α-L-aspartyl-L-phenylalanine-α-methyl ester

#95
20100222608
2010-09-02

Synthesis of N-[N-(3,3-dimethylbutyl)-L-α-aspartyl]-L-phenylalanine 1-methyl ester using 3,3-dimethylbutyraldehyde precursors

#96
20100152098
2010-06-17

Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof

#97
20100144649
2010-06-10

Compounds for enzyme inhibition

#98
20100144648
2010-06-10

Compounds for enzyme inhibition

#99
20100113770
2010-05-06

O-SUBSTITUTED HYDROXYARYL DERIVATIVES

#100
20100113328
2010-05-06

Targeted delivery to legumain-expressing cells

#101
20100105864
2010-04-29

PROPHYLACTIC OR THERAPEUTIC AGENT FOR DIARRHEA

#102
20100048921
2010-02-25

PHARMACEUTICALLY ACTIVE COMPOUNDS

#103
20090286763
2009-11-19

AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF

#104
20090239809
2009-09-24

Process for preparing peptide products for promoting cholecystokinin secretion and use of the peptide products

#105
20090191600
2009-07-30

Method for producing α-L-aspartyl-L-phenylalanine-β-ester and method for producing α-L-aspartyl-L-phenylalanine-α-methyl ester

#106
20090163844
2009-06-25

Methods for the treatment or prevention of scars and/or keloids

#107
20090143248
2009-06-04

Biologically active C-terminal arginine-containing peptides

#108
20090093541
2009-04-09

Melanin eliminator preparation

#109
20090069536
2009-03-12

Amide forming chemical ligation

#110
20090042788
2009-02-12

Peptides and chemical compound for inhibition of SHP2 function

#111
20090036525
2009-02-05

Non-Natural Amino Acid Derivatives

#112
20080318957
2008-12-25

POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF

#113
20080293634
2008-11-27

C-Met receptor regulation by angiotensin IV (AT) receptor ligands

#114
20080287649
2008-11-20

Methods for the synthesis of cyclic peptides

#115
20080275216
2008-11-06

Fluorous capping reagents and methods for peptide purification

#116
20080214648
2008-09-04

Hiv Prodrugs Cleavable by Cd26

#117
20080139456
2008-06-12

Macrocyclic Sh2 Domain Binding Inhibitors

#118
20080045744
2008-02-21

SYNTHESIS OF N-[N-(3,3-DIMETHYLBUTYL)-L-ALPHA-ASPARTYL]-L-PHENYLALANINE 1-METHYL ESTER USING 3,3-DIMETHYLBUTYRALDEHYDE PRECURSORS

#119
20080004215
2008-01-03

Peptides and chemical compound for inhibition of SHP2 function

#120
20070293465
2007-12-20

Compounds for enzyme inhibition

#121
20070293442
2007-12-20

Antithrombotic compound

#122
20070275900
2007-11-29

Prodrugs cleavable by CD26

#123
20070135356
2007-06-14

Amino acid conjugates providing for sustained systemic concentrations of GABA analogues

#124
20070123469
2007-05-31

N- or C- terminally modified small peptides

#125
20070106086
2007-05-10

Process for the preparation of 3,3-dimethylbutanal

#126
20070060773
2007-03-15

Amide forming chemical ligation

#127
20060287280
2006-12-21

Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX

#128
20060194947
2006-08-31

Peptide gap junction modulators

#129
20060135480
2006-06-22

Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex

#130
20060135410
2006-06-22

Targeted delivery to legumain-expressing cells

#131
20060122100
2006-06-08

Melanin extinguisher

#132
20060111553
2006-05-25

Novel thrombin inhibitors, the preparation and use thereof

#133
20060100160
2006-05-11

Amino acid derived prodrugs of propofol, compositions and uses thereof

#134
20060094718
2006-05-04

O-substituted hydroxyaryl derivatives

#135
20060083847
2006-04-20

Glycopeptide and peptide having a taste imparting function, and method of imparting the taste to foods

#136
20050245759
2005-11-03

Process for producing cinnamaldehyde derivatives, use thereof and the like

#137
20050175755
2005-08-11

Process for production of aspartyl dipeptide ester derivative, novel production intermediate therefor, and process for production thereof

#138
20050124035
2005-06-09

Method for producing α-L-aspartyl-L-phenylalanine-β-ester and method for producing α-L-aspartyl-L-phenylalanine-α-methyl ester

#139
20050101764
2005-05-12

Process for the preparation of peptides

#140
20050095248
2005-05-05

Suppression of immune response via inhibition of cathepsin S

#141
20050080010
2005-04-14

Suppression of immune response via inhibition of cathepsin S

#142
20050049406
2005-03-03

Isotopically coded affinity markers 3

#143
20050014972
2005-01-20

Novel intermediate for sweetener with high sweetness and process for producing the same

#144
20050014967
2005-01-20

Synthesis of N-[N-(3,3-dimethylbutyl)-L-α-aspartyl]-L-phenylalanine 1-methyl ester using oxazolidinone derivatives